Phagocytosis of platelet microvesicles and β2– glycoprotein I

Summary

The majority of the antiphospholipid antibodies, present in patients with antiphospholipid syndrome, are directed against conformational epitopes in β2-glycoprotein I. β2-glycoprotein I is an anionic phospholipid- binding 50-kDa plasma protein whose physiological role is not clear. Here we investigate the role of β2-glycoprotein I in the phagocytosis of phosphatidylserine-expressing platelet microvesicles and the effect of autoantibodies to β2-glycoprotein I on this process. We labelled the glycans of β2-glycoprotein I with BODIPY (4,4-difluoro- 4-bora-3a,4a-diaza-s-indacene)-hydrazide without affecting its phospholipid binding capacity. BODIPY-β2-glycoprotein I bound to platelet microvesicles in a concentration-dependent manner and promoted the phagocytosis of platelet microvesicles by THP-1 derived macrophages in vitro at physiological plasma concentrations with a half maximal effect at ∼10 μg/ml. β2-glycoprotein I-stimulated phagocytosis was inhibited by annexin A5 and the phosphatidylserine-binding C1C2 fragment of lactadherin. Furthermore, immunoaffinity purified β2-glycoprotein I-dependent antiphospholipid antibodies from five patients with antiphospholipid syndrome inhibited the phagocytosis in a concentration- dependent manner. These studies suggest that the binding of β2-glycoprotein I to phosphatidylserine-expressing procoagulant platelet microvesicles may promote their clearance by phagocytosis and autoantibodies to β2-glycoprotein I may inhibit this process to induce a procoagulant state.

Keywords

β2-glycoprotein I - antiphospholipid antibodies - platelet microvesicles - phagocytosis

^* These two authors contributed equally.

• References

• 1 Reid KB, Day AJ. Structure-function relationships of the complement components. Immunol Today 1989; 10: 177-180.
• 2 Bendixen E, Halkier T, Magnusson S. et al. Complete primary structure of bovine beta 2-glycoprotein I: localization of the disulfide bridges. Biochemistry 1992; 31: 3611-3617.
• 3 Schwarzenbacher R, Zeth K, Diederichs K. et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphosp-holipid syndrome. EMBO J 1999; 18: 6228-6239.
• 4 Igarashi M, Matsuura E, Igarashi Y. et al. Human beta2-glycoprotein I as an anti-cardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 1996; 87: 3262-3270.
• 5 Sheng Y, Sali A, Herzog H. et al. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996; 157: 3744-3751.
• 6 Hammel M, Schwarzenbacher R, Gries A. et al. Mechanism of the interaction of beta(2)-glycoprotein I with negatively charged phospholipid membranes. Bio-chemistry 2001; 40: 14173-14181.
• 7 Nimpf J, Bevers EM, Bomans PH. et al. Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta 1986; 884: 142-149.
• 8 Thiagarajan P, Le A, Benedict CR. Beta(2)-glycoprotein I promotes the binding of anionic phospholipid vesicles by macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 2807-2811.
• 9 Finlayson JS, Mushinski JF. Separation of subfractions of human beta-2-glyco-protein I. Biochim Biophys Acta 1967; 147: 413-420.
• 10 Shao C, Novakovic VA, Head JF. et al. Crystal structure of lactadherin C2 domain at 1.7 angstrom resolution with mutational and computational analyses of its membrane-binding motif. J Biol Chem 2008; 283: 7230-7241.
• 11 Dasgupta SK, Abdel-Monem H, Niravath P. et al. Lactadherin and clearance of platelet-derived microvesicles. Blood 2009; 113: 1332-1339.
• 12 Thiagarajan P, Le A, Shapiro SS. Characterization of beta2-glycoprotein I-dependent and -independent “antiphospholipid” antibodies from lupusprone NZW/BXSB F1 hybrid male mice. Am J Hematol 1997; 56: 86-92.
• 13 Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265: 17420-17423.
• 14 Hoffmeister KM, Josefsson EC, Isaac NA. et al. Glycosylation restores survival of chilled blood platelets. Science 2003; 301: 1531-1534.
• 15 Gushiken FC, Le A, Arnett FC. et al. Polymorphisms beta2-glycoprotein I: phospholipid binding and multimeric structure. Thromb Res 2002; 108: 175-180.
• 16 Cavazzana A, Pengo V, Tonello M. et al. Anti-beta(2)-glycoprotein I ELISA assay: The influence of different antigen preparations. Thromb Haemost 2009; 101: 789-791.
• 17 Pengo V, Thiagarajan P, Shapiro SS. et al. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70: 69-76.
• 18 Galli M, Comfurius P, Maassen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.
• 19 Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005; 62: 971-988.
• 20 Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and plateletderived microparticles. J Biol Chem 1991; 266: 24302-24307.
• 21 Pereira J, Alfaro G, Goycoolea M. et al. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost 2006; 95: 94-99.
• 22 Jy W, Tiede M, Bidot CJ. et al. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res 2007; 121: 319-325.
• 23 Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987; 03: 123-193.
• 24 Oja CD, Semple SC, Chonn A. et al. Influence of dose on liposome clearance: critical role of blood proteins. Biochim Biophys Acta 1996; 1281: 31-37.
• 25 Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unila-mellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992; 267: 18759-18765.
• 26 Chonn A, Semple SC, Cullis PR. Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of “nonself” particles. J Biol Chem 1995; 270: 25845-25849.
• 27 Bondanza A, Sabbadini MG, Pellegatta F. et al. Anti-beta2 glycoprotein I anti-bodies prevent the Deactivation of platelets and sustain their phagocytic clearance. J Autoimmun 2000; 15: 469-477.
• 28 Bondanza A, Manfredi AA, Zimmermann VS. et al. Anti-beta2 glycoprotein I anti-bodies cause inflammation and recruit dendritic cells in platelet clearance. Thromb Haemost 2001; 86: 1257-1263.
• 29 Maiti SN, Balasubramanian K, Ramoth JA. et al. Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J Biol Chem 2008; 283: 3761-3766.
• 30 Brighton TA, Hogg PJ, Dai YP. et al. Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol 1996; 93: 185-194.
• 31 Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34.
• 32 Galli M, Bevers EM. Inhibition of phospholipid-dependent coagulation reactions by 'antiphospholipid antibodies': possible modes of action. Lupus 1994; 03: 223-228.
• 33 Galli M, Luciani D, Bertolini G. et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
• 34 Pierangeli SS, Chen PP, Raschi E. et al. Antiphospholipid antibodies and the anti-phospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236-250.
• 35 Urbanus RT, Derksen RH, de Groot PG. Platelets and the antiphospholipid syndrome. Lupus 2008; 17: 888-894.
• 36 Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104: 2353-2358.
• 37 Cockrell E, Espinola RG, McCrae KR. Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus 2008; 17: 943-951.
• 38 Meroni PL, Raschi E, Testoni C. et al. Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphosp-holipid antibodies. Autoimmun Rev 2004; 03: 510-515.
• 39 Rand JH, Wu XX, Andree HA. et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood 1998; 92: 1652-1660.
• 40 Oosting JD, Derksen RH, Bobbink IW. et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-2625.
• 41 Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67: 649-653.
• 42 Yasuda S, Tsutsumi A, Chiba H. et al. beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000; 152: 337-346.
• 43 Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 2007; 07: 964-974.
• 44 Maniati E, Potter P, Rogers NJ. et al. Control of apoptosis in autoimmunity. J Pathol 2008; 214: 190-198.
• 45 Danowski A, Kickler TS, Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphosp-holipid syndrome and systemic lupus erythematosus. J Rheumatol 2006; 33: 1775-1779.
• 46 Zoller B, Garcia de Frutos P, Hillarp A. et al. Thrombophilia as a multigenic disease. Haematologica 1999; 84: 59-70.